Compare Stocks: PHAR, EGY, GKP, and CNE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNE Canacol Energy	C$1.53	C$1.53	C$1.33 ▼ C$4.45	C$52.20M	1.117311	38,466 shs	N/A
EGY Vaalco Energy	$6.03 +0.4%	$5.86	$3.36 ▼ $6.72	$632.20M	0.24	1.43 million shs	1.24 million shs
PHAR Pharming Group	$9.79 +2.7%	$10.95	$9.44 ▼ $21.34	$692.92M	-0.05	33,665 shs	3,332 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNE Canacol Energy	0.00%	0.00%	0.00%	0.00%	-34.62%
EGY Vaalco Energy	0.00%	+5.24%	-3.48%	+14.87%	+49.88%
PHAR Pharming Group	0.00%	+0.41%	-8.94%	-29.37%	-33.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNE Canacol Energy	C$1.53	C$1.53	C$1.33 ▼ C$4.45	C$52.20M	1.117311	38,466 shs	N/A
EGY Vaalco Energy	$6.03 +0.4%	$5.86	$3.36 ▼ $6.72	$632.20M	0.24	1.43 million shs	1.24 million shs
PHAR Pharming Group	$9.79 +2.7%	$10.95	$9.44 ▼ $21.34	$692.92M	-0.05	33,665 shs	3,332 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNE Canacol Energy	0.00%	0.00%	0.00%	0.00%	-34.62%
EGY Vaalco Energy	0.00%	+5.24%	-3.48%	+14.87%	+49.88%
PHAR Pharming Group	0.00%	+0.41%	-8.94%	-29.37%	-33.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNE Canacol Energy	0.00	N/A	N/A	N/A
EGY Vaalco Energy	1.50	Reduce	$7.30	21.16% Upside
PHAR Pharming Group	2.20	Hold	$38.67	294.96% Upside

Current Analyst Ratings Breakdown

Latest PHAR, EGY, GKP, and CNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$38.00
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
8/7/2026	EGY Vaalco Energy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNE Canacol Energy	C$319.09M	0.16	C$0.42 per share	3.68	C$11.30 per share	0.14
EGY Vaalco Energy	$359.27M	1.76	$1.02 per share	5.91	$4.25 per share	1.42
PHAR Pharming Group	$376.13M	1.84	$0.20 per share	48.81	$3.95 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNE Canacol Energy	C$16.10M	C$1.14	1.34	N/A	N/A	23.28%	8.64%	8.32%	N/A
EGY Vaalco Energy	-$41.39M	-$1.06	N/A	25.10	N/A	-31.11%	-14.36%	-6.41%	11/9/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	81.58	36.26	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest PHAR, EGY, GKP, and CNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
11/5/2026	Q3 2026	PHAR Pharming Group	$0.12	N/A	N/A	N/A	$103.54 million	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNE Canacol Energy	N/A	32.00%	N/A	N/A	N/A
EGY Vaalco Energy	$0.25	4.15%	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Latest PHAR, EGY, GKP, and CNE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2026	EGY Vaalco Energy	quarterly	$0.0625	4.22%	8/21/2026	8/21/2026	9/22/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNE Canacol Energy	187.55	0.59	1.34
EGY Vaalco Energy	0.60	0.44	0.41
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNE Canacol Energy	31.46%
EGY Vaalco Energy	50.32%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
CNE Canacol Energy	20.60%
EGY Vaalco Energy	3.00%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNE Canacol Energy	396	34.12 million	N/A	Not Optionable
EGY Vaalco Energy	281	105.19 million	102.04 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable

PHAR, EGY, GKP, and CNE Headlines

Recent News About These Companies

Pharming Group (NASDAQ:PHAR) Reaches New 12-Month Low - Here's Why

October 7, 2026 | marketbeat.com

HC Wainwright Raises Earnings Estimates for Pharming Group

October 2, 2026 | marketbeat.com

Grifols (NASDAQ:GRFS) & Pharming Group (NASDAQ:PHAR) Head to Head Contrast

October 2, 2026 | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Rating of "Hold" from Brokerages

October 2, 2026 | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Rated "Hold" by Wall Street Analysts

October 2, 2026 | marketbeat.com

Q3 EPS Estimates for Pharming Group Boosted by HC Wainwright

October 1, 2026 | americanbankingnews.com

Analysts Issue Forecasts for Pharming Group Q3 Earnings

October 1, 2026 | marketbeat.com

Pharming: Chief Executive Officer Fabrice Chouraqui Steps Down with Immediate Effect

September 30, 2026 | ideal-investisseur.frI

Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs

September 29, 2026 | finance.yahoo.com

Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

September 29, 2026 | pharmexec.comP

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

September 29, 2026 | marketbeat.com

Pharming Group N.V.: Pharming announces CEO transition

September 29, 2026 | finanznachrichten.de

Pharming CEO Fabrice Chouraqui Steps Down, Names Leverne Marsh, Kenneth Lynard Interim Co-CEOs

September 29, 2026 | rttnews.com

Pharming CEO Fabrice Chouraqui Resigns After Disagreement on Direction

September 29, 2026 | marketwatch.com

Pharming announces CEO transition

September 29, 2026 | globenewswire.com

FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS

September 26, 2026 | rttnews.com

Pharming Group N.V. Announces U.S. FDA Acceptance And Priority Review Of sNDA For Lower Doses Of Joenja To Treat Children With APDS

September 25, 2026 | marketscreener.comM

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Time to Buy?

September 25, 2026 | marketbeat.com

Pharming Says FDA Accepts sNDA for Lower-Dose Joenja in Children With APDS

September 25, 2026 | marketscreener.comM

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

September 25, 2026 | globenewswire.com

Pharming Group's (PHAR) Buy Rating Reaffirmed at HC Wainwright

September 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, EGY, GKP, and CNE Company Descriptions

Canacol Energy TSE:CNE

C$1.53 0.00 (0.00%)

As of 12/30/2025

Canacol is a natural gas exploration and production company with operations focused in Colombia.

Vaalco Energy NYSE:EGY

$6.02 +0.03 (+0.42%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$6.02 -0.01 (-0.17%)

As of 10/9/2026 07:53 PM Eastern

VAALCO Energy, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids in Gabon, Egypt, Equatorial Guinea, and Canada. The company holds 58.8% interest in the Etame production sharing contract related to the Etame Marin block covering an area of approximately 46,200 gross acres located offshore in the Republic of Gabon in West Africa. It also owns 100% interest in the Eastern Desert, which contains West Gharib, West Bakr and North West Gharib merged concessions covering as area of approximately 45,067 acres, as well as Western Desert, which contains the South Ghazalat concession covering as area of approximately 7,340 acres located in Egypt. In addition, the company production and working interests in Cardium light oil and Mannville liquids-rich gas assets covering as area of 47,400 gross acres located near the north of Calgary, Alberta; and an undeveloped block offshore Equatorial Guinea, West Africa. VAALCO Energy, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.

Pharming Group NASDAQ:PHAR

$9.79 +0.26 (+2.73%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.77 -0.02 (-0.20%)

As of 10/9/2026 07:30 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, EGY, GKP, and CNE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, EGY, GKP, and CNE Earnings

Compare Dividends

Latest PHAR, EGY, GKP, and CNE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, EGY, GKP, and CNE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, EGY, GKP, and CNE Company Descriptions

Canacol Energy TSE:CNE

Vaalco Energy NYSE:EGY

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, EGY, GKP, and CNE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, EGY, GKP, and CNE Earnings

Compare Dividends

Latest PHAR, EGY, GKP, and CNE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, EGY, GKP, and CNE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, EGY, GKP, and CNE Company Descriptions

Canacol Energy TSE:CNE

Vaalco Energy NYSE:EGY

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools